TIVA with Propofol and Remifentanil for Laparoscopic Cholecystectomy
For laparoscopic cholecystectomy, administer remifentanil at 0.5-1 mcg/kg/min with propofol (100-200 mcg/kg/min or target-controlled infusion at 2.5-3 mcg/mL) for induction, then maintain with remifentanil 0.25 mcg/kg/min and propofol adjusted to surgical depth, titrating remifentanil in 25-50% increments as needed for surgical stimulation. 1
Induction Protocol
Start with remifentanil infusion at 0.5-1 mcg/kg/min combined with propofol for loss of consciousness 1. If intubation will occur within 8 minutes, give an initial remifentanil bolus of 1 mcg/kg over 30-60 seconds 1. Never use remifentanil alone for induction—loss of consciousness cannot be assured, and you risk apnea, muscle rigidity, and tachycardia 1.
For propofol dosing during induction:
- Target-controlled infusion: Set initial target at 3-4 mcg/mL 2
- Manual infusion: Titrate to loss of consciousness, typically 2 mg/kg bolus 3
Critical pitfall: Administer a muscle relaxant (e.g., atracurium 0.5 mg/kg or rocuronium 0.6 mg/kg) prior to or concurrent with remifentanil to prevent muscle rigidity, which drops from 20% incidence to <1% with this approach 1.
Maintenance Dosing
After intubation, reduce remifentanil to 0.25 mcg/kg/min when combined with propofol at 100-200 mcg/kg/min 1. This combination provides optimal surgical conditions while minimizing hemodynamic instability.
Titration algorithm:
- For inadequate analgesia or surgical stimulation: Increase remifentanil by 25-100% increments every 2-5 minutes 1
- For light anesthesia: Give supplemental remifentanil boluses of 1 mcg/kg every 2-5 minutes 1
- At infusion rates >1 mcg/kg/min: Consider increasing propofol depth rather than further remifentanil escalation 1
Target-controlled infusion approach yields remifentanil effect-site concentrations of 2.75 ng/mL (ED90) for adequate surgical anesthesia 4, though measured values show considerable interindividual variation 2.
Hemodynamic Management
Expect systolic blood pressure to decrease from baseline ~144 mmHg to ~101 mmHg after induction 2. This propofol-remifentanil combination causes more hypotension (16% incidence) compared to volatile agents (5%) 1, but maintains superior hemodynamic stability during pneumoperitoneum 5.
Management strategy:
- Have vasopressors immediately available (ephedrine or phenylephrine)
- Consider atropine pretreatment to blunt bradycardia risk 1
- During gallbladder manipulation, only 1.7% of TIVA patients require antihypertensive intervention versus 17.2% with volatile agents 5
Recovery and Emergence
Continue both agents until surgical closure. The FDA label explicitly states remifentanil can be infused to the end of surgery without delaying emergence 1. Stop both infusions at skin closure.
Expected recovery times 6:
- Time to extubation: 7.4 ± 2.1 minutes
- Time to Aldrete score ≥9: 23.1 ± 4.8 minutes
- PACU discharge: 40 minutes (median)
These times are significantly faster than volatile anesthesia and result in 50% reduction in PONV incidence (20% vs 38%) 6, 5.
Postoperative Analgesia Transition
Do not use remifentanil boluses for postoperative pain management 1. The ultra-short duration leaves patients with acute opioid tolerance and no residual analgesia.
Transition strategy:
- Administer longer-acting opioids (fentanyl, morphine) 30-45 minutes before emergence
- Expect 70-88% of patients to require fentanyl in PACU 5
- Multimodal analgesia (NSAIDs, local anesthetics) should be standard
Key Advantages Over Volatile Anesthesia
This TIVA technique provides superior outcomes for laparoscopic cholecystectomy 6:
- 47% reduction in PONV (20% vs 38%)
- 18% faster extubation
- 21% shorter PACU stay
- Better hemodynamic control during pneumoperitoneum
- Higher 24-hour quality of recovery scores
The evidence consistently demonstrates that propofol-remifentanil TIVA optimizes early recovery and reduces morbidity compared to sevoflurane-based techniques 6, 7, making it the preferred anesthetic approach for this procedure when prioritizing patient outcomes.